FOXC1蛋白在弥漫大B细胞淋巴瘤中的表达及与患者预后的关系

The expression of FOXC1 protein in diffuse large B-celllymphoma and its correlation with prognosis

目的:探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)中叉头框蛋白C1(forkhead box C1,FOXC1)蛋白的表达情况及临床病理意义,并评估其在患者预后判断方面的潜在价值。方法:对2018年4月至2022年3月惠州市第一人民医院经病理学诊断的33例DLBCL患者进行回顾性分析,利用免疫组织化学技术对FOXC1蛋白表达水平进行检测,收集患者的随访信息,并分析其表达水平与临床病理参数以及患者预后的相关性。利用GEPIA2数据库分析FOXC1在DLBCL中表达情况及其与BCL-2的相关性;利用UCSC数据库进行FOXC1在泛癌中的生存分析;利用HPA数据库和STRING数据库分析与FOXC1直接相互作用的蛋白。结果:33例DLBCL组织中FOXC1阳性表达17例(51.5%),12例淋巴组织反应性增生(reactive lymphoid hyperplasia, RH)中FOXC1阳性表达0例(0.0%),两者差异有统计学意义(P<0.01)。统计分析结果表明,在DLBCL中,FOXC1蛋白的表达水平与患者的Ann Arbor临床分期和BCL-2的表达情况有关(P<0.01)。同时,FOXC1蛋白表达水平与DLBCL患者的预后密切相关,高表达患者的生存时间明显短于低表达患者(P<0.01)。GEPIA数据库分析结果显示,FOXC1在DLBCL中的表达高于正常组织,FOXC1与BCL-2表达正相关(P<0.01,R=0.36)。UCSC数据库分析显示,FOXC1在包括DLBCL的4种肿瘤中与患者预后相关(P<0.05)。结论:本研究发现DLBCL中FOXC1蛋白表达水平升高,其高表达与患者的不良预后相关,提示FOXC1有可能成为DLBCL预后评估的潜在分子标志。

Objective:To investigate the expression of FOXC1 in diffuse large B-cell lymphoma(DLBCL)and its clinicopathological significance,and to evaluate its potential value in prognosis.Methods:A retrospective analysis was performed on 33 cases of DLBCL diagnosed by pathology in Huizhou First People's Hospital from April 2018 to March 2022.FOXC1 protein expression was detected by immunohistochemistry.Follow-up information was collected and the correlation between the expression level and clinicopathological parameters and prognosis of patients was analyzed.The expression of FOXC1 in DLBCL and its correlation with BCL-2 were analyzed using GEPIA2 database.The UCSC database was used to analyze the survival of FOXC1 in pan-carcinoma.The proteins that directly interact with FOXC1 were analyzed using HPA and STRING databases.Results:FOXC1 was positively expressed in 17(51.5%)of 33 DLBCL tissues and 0(0.0%)of 12 lymphoid reactive hyperplasia(RH)tissues,the difference between the two was statistically significant(P<0.01).The results of statistical analysis showed that the expression level of FOXC1 protein in DLBCL was related to the Ann Arbor clinical stage and the expression of BCL-2 in patients(P<0.01).At the same time,the expression level of FOXC1 protein was closely related to the prognosis of DLBCL patients,and the survival time of patients with high expression was significantly shorter than that of patients with low expression(P<0.01).The results of GEPIA database analysis showed that the expression of FOXC1 in DLBCL was higher than that in normal tissues,and FOXC1 was positively correlated with the expression of BCL-2(P<0.01,R=0.36).UCSC database analysis showed that FOXC1 was associated with patient outcomes in 4 tumors including DLBCL(P<0.05).Conclusion:This study found that the expression level of FOXC1 protein in DLBCL was increased,and its high expression was associated with poor prognosis of patients,suggesting that FOXC1 may be a potential molecular marker for prognosis assessment of DLBCL.